Roche keeps biosimilar erosion at bay but misses sales estimate

30 January 2020
roche_pharma_day_large

Swiss pharma giant Roche (ROG: SIX) is succeeding in replacing revenues lost to biosimilar competition to its older drugs.

The Basel-based company presented its financial results for the fourth quarter of 2019, and for the year as a whole, on Thursday, after which the firm’s share price rose by 0.8% during the first four hours of trading.

Offsetting the decline of the big three

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology